pMSNC@ISG15 siRNA significantly improved cardiac function, reduced fibrosis, and increased M2-type macrophages in a rat model of post-myocardial infarction heart failure.
Does pMSNC@ISG15 siRNA improve cardiac function and reduce fibrosis in a post-MI HF rat model?
Targeted gene therapy using pMSNC@ISG15 siRNA improves cardiac function and reduces fibrosis in a rat model of post-myocardial infarction heart failure.
Absolute Event Rate: 0% vs 0%
. In the post-MI HF rat model, treatment with pMSNC@ISG15 siRNA led to significant improvements in cardiac function, reduced fibrosis, and increased M2-type macrophages, highlighting its potential as a nanomedicine-based therapeutic strategy for HF. The study provides valuable insights into the use of nanocarriers for targeted gene therapy in cardiac diseases.
Shen et al. (Wed,) reported a other. pMSNC@ISG15 siRNA significantly improved cardiac function, reduced fibrosis, and increased M2-type macrophages in a rat model of post-myocardial infarction heart failure.